HCPCS code Q4165 – Keramatrix and Kerasorb skin substitutes

Key takeaways

HCPCS Code Q4165 covers two products only: Keramatrix and Kerasorb skin substitutes, not the broader Q4xxx series

Units are reported per square centimeter of wound area measured at the time of application, rounded up to the nearest whole unit

From January 1, 2026, Medicare pays Q4165 as an incident-to supply at a flat rate of about $127 per sq cm

Medicare coverage needs a covered diagnosis and full documentation at each application, judged by your MAC’s LCD or case by case

Medicare pays only the product applied, so discarded units are never billed and JW/JZ modifiers no longer go on Q4165 lines

Practice management software like Pabau keeps wound measurements, product details, and prior auth status on the record that feeds the claim

HCPCS Code Q4165: official descriptor and product coverage

HCPCS Code Q4165 is the official HCPCS Level II code for “Keramatrix or Kerasorb, per square centimeter.” Both products are keratin-based skin substitutes applied topically to chronic wounds to support tissue regeneration. The descriptor covers both product names under a single billable code, so a coder billing either Keramatrix or Kerasorb uses Q4165 on the claim.

Q-codes are temporary HCPCS Level II codes maintained by the Centers for Medicare and Medicaid Services. New and revised drug and biological codes are decided through a quarterly application review, and CMS has held no public meetings for them since 2020. CMS can also retire or reassign a Q-code. Verify the code remains active in the current year’s CMS HCPCS file before billing.

How to calculate units for Q4165

Units for HCPCS Code Q4165 equal the wound surface area in square centimeters at the time of application. Measure wound length and width in centimeters, multiply to get area, and round up to the nearest whole square centimeter. That figure is the billed quantity on the claim.

A worked example: a wound measuring 3.2 cm x 2.7 cm gives an area of 8.64 sq cm. Round up to 9. Bill Q4165 with a quantity of 9 units.

• Measure at application, not at initial presentation: wound size changes between visits; document measurement in the note for the date of service billed.
• Bill the covered area: if the product covers only part of a larger wound, bill for the area covered, not the total wound size.
• Document the formula: record both the length and width measurements in the clinical note so the unit calculation is auditable.
• Check payer and MAC guidance: some MACs publish maximum application limits per encounter; verify before billing large quantities.

Keramatrix and Kerasorb: products covered under Q4165

Keramatrix and Kerasorb are keratin-based wound products made from purified keratin protein sourced from sheep’s wool. They support chronic wound healing by providing a resorbable scaffold for cellular ingrowth. Keramatrix is cleared by the FDA through the 510(k) pathway rather than licensed as a biologic. That status places Q4165 in the incident-to supply group CMS created for 2026 payment.

When ordering or applying either product, verify the lot number and package size in the clinical record. CMS and MAC audits have flagged missing lot documentation as a compliance risk for skin substitute claims.

Medicare coverage and covered indications for Q4165

Medicare coverage for HCPCS Code Q4165 depends on your Medicare Administrative Contractor (MAC). The skin substitute Local Coverage Determinations (LCDs) planned for January 1, 2026 were withdrawn in December 2025. Novitas, First Coast, and CGS keep their older skin substitute LCDs. Palmetto GBA, NGS, WPS, and Noridian have none, so they judge each claim on whether it is reasonable and necessary.

Under the older LCDs, conventional wound care must have been tried and failed before the skin substitute is applied. The wound must also meet minimum duration and severity criteria. Case-by-case reviewers look for the same evidence in the record, so document it either way.

• Diabetic foot ulcers (DFU) – partial- or full-thickness diabetic foot wounds that have not healed with standard care over the LCD-defined minimum period.
• Venous leg ulcers (VLU) – chronic venous stasis ulcers that have failed compression therapy and standard wound care per LCD criteria.
• Pressure ulcers (Stage 3 or 4) – pressure injuries that meet the MAC’s definition of medically necessary skin substitute application.
• Surgical wounds – post-surgical wounds where standard healing has not progressed, covered under specific LCD language.

What Q4165 does not cover

Claims submitted for wound types outside LCD coverage are denied automatically. Common non-covered uses include acute traumatic wounds without underlying chronic disease, cosmetic skin procedures, and burns not meeting clinical criteria. Wounds that have not first received adequate conventional wound care are also denied. Where your MAC has an LCD, it defines “adequate conventional care” in its own terms. Review that LCD, or your MAC’s reasonable-and-necessary guidance, before the first application.

2026 Medicare fee schedule and reimbursement for Q4165

Medicare pays HCPCS Code Q4165 at a flat national rate of about $127.14 to $127.28 per square centimeter in 2026. The CY2026 Physician Fee Schedule and OPPS final rules reclassified skin substitutes that are not licensed as biologics as incident-to supplies. Keramatrix, a 510(k)-cleared product, falls in that group from January 1, 2026.

The flat rate replaced product-specific Average Sales Price (ASP) pricing, and manufacturers no longer report ASP data for these products. CMS set the rate for the full calendar year, so it does not change quarterly. The same rate applies in the physician office, the hospital outpatient department, and the ambulatory surgical center. Verify your local rate using the CMS Physician Fee Schedule lookup tool.

Commercial payers including Blue Cross Blue Shield plans set their own payment rates, which may differ significantly from the Medicare flat rate. Review each payer’s fee schedule or contact the payer directly for Q4165 contracted rates. Load each contracted rate into your fee schedule separately, because a commercial Q4165 line will not follow the Medicare figure.

ICD-10-CM diagnosis codes to use with Q4165

Every Q4165 claim needs a supporting ICD-10-CM diagnosis code that maps to a covered wound type. In Novitas, First Coast, and CGS jurisdictions, a code missing from the LCD’s covered-diagnosis list triggers a denial. The table below lists the most commonly linked codes for each covered wound category.

Where your MAC has an LCD, verify the specific ICD-10 codes on its covered-diagnosis list, not just the broad category. Codes missing from that list trigger denial even when the wound is clinically appropriate. Where the MAC has no LCD, code to the highest specificity the documentation supports, including site, laterality, and severity.

Required modifiers when billing Q4165

Modifier requirements for HCPCS Code Q4165 changed on January 1, 2026, when Medicare began paying the product as an incident-to supply. The payer, the patient’s hospice status, and wound laterality now decide which modifiers apply. Confirm modifier guidance with your MAC and each commercial payer before billing.

The JW/JZ modifier pair applies to separately payable drugs and biologicals from single-dose containers. CMS guidance states the pair is not appropriate on incident-to supplies, and Q4165 has been one on Medicare claims since January 1, 2026. Bill only the square centimeters applied to the wound. Medicare does not pay for discarded skin substitute product under any circumstance. A commercial payer may keep its own waste-reporting rule, so check its policy before you drop the modifiers from its claims.

Prior authorization requirements for Q4165

Prior authorization for HCPCS Code Q4165 is not universally required, and the rules vary by payer and MAC jurisdiction. Check PA for the patient’s primary payer as part of eligibility verification, before the first application appointment.

• Medicare (Traditional / FFS): Traditional Medicare does not require prior authorization for Q4165 under current CMS policy. MAC LCDs may still require documentation of prior treatment failure before the first application. Some MACs have implemented pre-claim review programs for high-utilization skin substitute codes.
• Medicare Advantage plans: MA plans set their own prior auth requirements. Many require PA for any skin substitute application. Verify with each MA plan before scheduling.
• Commercial payers (BCBS, Aetna, UHC, Cigna): Most commercial plans require prior authorization for skin substitutes. BCBS has a published medical policy for bioengineered skin and soft tissue substitutes that includes specific clinical criteria the patient must meet.
• Palmetto GBA: As the MAC for Jurisdictions J and M, Palmetto GBA has no published skin substitute LCD for 2026. It reviews Q4165 claims case by case, so the wound history, measurements, and prior care in the record have to justify each application.

Q4165 vs Q4166: how to choose the right code

Q4165 and Q4166 are adjacent HCPCS codes covering different wound matrix products. Using Q4166 when Q4165 is correct, or vice versa, results in an automatic product-code mismatch denial. The differentiator is simple: the product applied determines the code.

Both codes are per-square-centimeter skin substitutes, making them easy to confuse when billing from product logs or charge capture. The safest approach is to link the charge code directly to the product name in the clinical record. The coder then never has to infer which code applies. For other products in the Q4xxx series, check the current CMS HCPCS file, which lists each product under its own code.

Documentation requirements for Q4165 claims

Missing or incomplete documentation is the most common root cause of Q4165 denials on audit. Documentation rules for skin substitute codes are among the strictest in outpatient wound care. Every clinical note for a Q4165 application date must include all of the following elements to survive MAC review.

• Wound measurement at time of application: length and width in centimeters recorded in the note; must match the billed unit quantity.
• Wound photograph: dated photo at application showing wound bed, dimensions, and surrounding tissue, so a reviewer can confirm the measured area.
• Product identification: product name (Keramatrix or Kerasorb), lot number, package size, and expiration date.
• Physician order: signed order authorizing the skin substitute application, with the treating diagnosis.
• Prior treatment failure documentation: evidence that conventional wound care (debridement, moisture management, offloading) was used for the LCD-required duration before the first application.
• Application technique note: brief narrative of how the product was applied, wound bed preparation performed, and dressing used.
• Treatment plan: documented plan showing the intended application frequency and re-assessment schedule.

Charge capture should hold every field above before the claim is created, so the coder never reopens the chart to finish a Q4165 line.

Top reasons Q4165 claims are denied and how to prevent them

Skin substitute claims have appeared repeatedly on OIG Work Plan audits as Medicare spending on the category climbed. Q4165 denials follow a predictable pattern, and the same triggers appear across practices and MACs. The table below pairs each trigger with the step that prevents it.

When a Q4165 claim is denied, read the Claim Adjustment Reason Code (CARC) on the electronic remittance advice before appealing. The CARC pinpoints the denial category and directs the correct corrective action. Track denial patterns across Q4165 claims over a rolling 90-day period. That surfaces systemic documentation or coding errors instead of treating each denial as isolated. The medical billing denial codes reference explains what each common CARC value means and how to correct it.

Q4165 billing checklist for wound care coders

Use this pre-submission checklist before releasing any Q4165 claim. Each item maps to a denial trigger, and missing any one gives the payer grounds to reject the claim.

The four stages below show where each checklist item sits on the path from coverage check to payment.

• Product confirmed: Keramatrix or Kerasorb was applied (not a different Q4xxx product).
• Wound measured at service date: Length and width in cm recorded; unit quantity = area rounded up to nearest whole sq cm.
• ICD-10 code verified: Diagnosis is on your MAC’s LCD covered-diagnosis list, or supports medical necessity where the MAC has no LCD.
• Waste not billed: Only product applied to the wound is billed, with no JW or JZ on 2026 Medicare lines.
• Prior auth status confirmed: PA obtained for MA and commercial plans that require it, with the PA reference number recorded on the claim.
• Clinical note complete: Wound photo, product lot number, physician order, and prior treatment failure documentation all present.
• Place of service correct: POS code matches the setting where the service took place (11, 22, or 24).
• Application CPT coded: The skin substitute application code from the 15271-15278 series is on the same claim. Q4165 covers the product, not the procedure.

The application procedure bills on its own line. CPT code 15271 covers the first 25 sq cm on the trunk, arms, or legs, while foot wounds use 15275. Build this checklist into charge capture so errors are caught before the claim leaves the practice.

How claims management software supports Q4165 billing

Most Q4165 denials start in the chart. The wound measurement sits in one note, the lot number on a packing slip, and the prior auth reference in an inbox. A coder then rebuilds the claim line from all three sources.

Practice management software like Pabau keeps those details on the patient record. Treatment notes, wound photos, and product lot details are captured at the appointment itself. Its claims software built for practices then pulls that record data into a pre-filled claim, submitted and tracked through Claim.MD.

The coder reviews one complete record instead of chasing three, and remittances post back against the same claim. On a code that attracts close audit attention, that shortens the path from application to payment.

Stop losing Q4165 claims to missing documentation

Pabau keeps wound measurements, lot details, and photos on one patient record. It pulls them into a pre-filled claim, so Q4165 lines reach the payer complete.

Book a demo

Conclusion

HCPCS Code Q4165 now pays a flat supply rate, so the 2026 margin sits in the units you can prove. Every square centimeter billed needs a matching measurement in the note, and trimmed product is never paid. Before the first application, check whether your MAC still works from an LCD, because that decides which criteria the record has to meet.

Update your fee schedule and charge rules once for the year, drop JW/JZ from Medicare lines, and hold every claim until the record is complete. The trade-off is a slower charge entry step in exchange for fewer appeals. Book a demo to see how Pabau keeps Q4165 wound documentation and claims on one record.

Continue your research

Need to understand how clearinghouse submission works for HCPCS claims? Medical claims clearinghouse guide explains how claims route from practice to payer and where Q-code claims most often stall.

Want to reduce claim rejections across your billing workflow? Medical billing overview covers the end-to-end process and where skin substitute claims fit within it.

Looking for the denial code definitions behind your Q4165 rejections? Denial codes in medical billing maps CARC values to actionable corrections for wound care coders.

Frequently asked questions